BioMarin Announces Pricing of $850mln Senior Notes and Completion of Syndication
ByAinvest
Thursday, Jan 29, 2026 4:21 pm ET1min read
BMRN--
FOLD--
BioMarin Pharmaceutical has priced a $850 million senior unsecured notes offering with a 5.500% interest rate due 2034. The issue price is 100.000% and the offering is expected to close on February 12, 2026, subject to customary closing conditions. BioMarin also completed the syndication of a new $2 billion senior secured term loan facility in connection with its pending acquisition of Amicus Therapeutics.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet